Biosimilar uptake by British local formularies: a cross sectional study

Background Biological medicines are starting to lose their patent protection, so similar, inexact copies (biosimilars) are being developed and licensed. The high acquisition costs of biologics for healthcare providers could be reduced by switching to biosimilars, thus alleviating budgetary pressures...

Descripción completa

Detalles Bibliográficos
Autores principales: Alnahar, Saja, Elliott, Rachel A., Smith, Murray D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686267/
https://www.ncbi.nlm.nih.gov/pubmed/28871421
http://dx.doi.org/10.1007/s11096-017-0523-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686267/
https://www.ncbi.nlm.nih.gov/pubmed/28871421
http://dx.doi.org/10.1007/s11096-017-0523-6

Ejemplares similares